BioStack Platforms Raises $9.5M Seed Led by Peak XV Partners for Clinical AI Data Pipelines

BioStack Platforms Closes $9.5M Seed Round

BioStack Platforms, a San Francisco-based startup founded in 2025, has raised a $9.5 million seed round led by Peak XV Partners. The funding was announced on October 22, 2026.

What BioStack Does

BioStack builds proprietary clinical and preclinical data pipelines that turn fragmented, unstructured biomedical records into ML-ready training and evaluation environments for healthcare and drug-discovery AI. In practical terms, the company serves AI labs that are building models on real clinical workflows, providing data, evaluations, rewards, and benchmarks.

The problem BioStack addresses is well known in healthcare AI: biomedical records are scattered across formats and systems, making them difficult to use for model training. BioStack's pipelines aim to convert that raw material into structured environments that AI developers can actually train and test against.

Founding Team and Background

The company was founded in 2025 by cancer genomics researcher Sanat Mishra, along with Akshat Nigam and Parth Patwa. BioStack is part of Y Combinator's Spring 2026 cohort, which gives it access to the accelerator's network and early-stage playbook.

The Investor Group

The seed round was led by Peak XV Partners. Additional investors include:

• Afore Capital
• Streamlined Ventures
• SV Angel
• Y Combinator
• DCVC
• Emerson Collective
• Verdict Capital

The presence of both generalist early-stage funds and healthcare- or deep-tech-focused investors reflects the dual nature of BioStack's business: it is an AI infrastructure company operating in a regulated, domain-specific market.

Why This Matters for Acquirers

BioStack occupies a specific and increasingly important layer in the healthcare AI stack: the data and evaluation layer. As more companies build clinical and drug-discovery models, demand for high-quality, ML-ready training environments is likely to grow. Acquirers in several categories could find BioStack relevant:

• Healthcare AI platforms looking to accelerate model development with better data pipelines
• Pharma and life sciences companies seeking to build or evaluate internal AI capabilities
• AI infrastructure providers wanting to add domain-specific data and evaluation tooling
• Cloud and data platform vendors expanding into regulated verticals

The company's focus on evaluations, rewards, and benchmarks is notable because those are often the hardest parts of deploying AI in clinical settings. A buyer would be acquiring not just data pipelines but also a methodology for measuring model performance on real clinical workflows.

What to Watch

BioStack is early-stage, founded in 2025 and backed by a seed round. Acquirers should monitor:

• Growth in the number of AI labs using its pipelines
• Expansion of preclinical and clinical data coverage
• Development of new evaluation and benchmark products
• Hiring and team growth following the seed round

BioStack has not disclosed specific customer names or revenue figures. The seed funding provides capital to build out its data pipelines and expand its customer base among healthcare and drug-discovery AI developers.